NASDAQ:FMTX Forma Therapeutics (FMTX) Stock Price, News & Analysis → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free FMTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$20.01▼$20.0150-Day Range$19.91▼$20.0152-Week Range$4.95▼$20.68Volume1 shsAverage Volume847,595 shsMarket Capitalization$957.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Forma Therapeutics alerts: Email Address Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Forma Therapeutics Stock (NASDAQ:FMTX)Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.Read More Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. FMTX Stock News HeadlinesSeptember 25, 2022 | finance.yahoo.comForma Therapeutics Holdings, Inc. (FMTX)September 7, 2022 | finance.yahoo.comBiotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & MoreApril 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."September 7, 2022 | apnews.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates GMTX, FMTX, SGFY, ECOMSeptember 7, 2022 | benzinga.comThe M&A Class Action Firm Announces the Investigation of Forma Therapeutics Holdings, Inc. - FMTXSeptember 2, 2022 | markets.businessinsider.com4 Analysts Have This to Say About Forma Therapeutics HldgsSeptember 2, 2022 | seekingalpha.comForma Therapeutics: Rare Disease PlaySeptember 1, 2022 | markets.businessinsider.comNovo Nordisk To Acquire Forma Therapeutics - Quick FactsApril 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."September 1, 2022 | finance.yahoo.comNovo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disordersSeptember 1, 2022 | marketwatch.comNovo Nordisk to Buy Forma Therapeutics for $1.1 Billion >FMTX NVOSeptember 1, 2022 | apnews.comFMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Forma Therapeutics, Holdings Inc. Is Fair to ShareholdersSeptember 1, 2022 | finance.yahoo.comForma Therapeutics to be acquired by Novo Nordisk in a cash deal valued at $1.1 billionSeptember 1, 2022 | finance.yahoo.comUPDATE 1-Novo Nordisk to acquire Forma Therapeutics in $1.1. bln dealAugust 11, 2022 | nasdaq.comForma Therapeutics Holdings, Inc. (NASDAQ:FMTX) up 28%, but insiders miss out having sold stock earlier this yearAugust 3, 2022 | msn.comRigel Pharma Expands Blood Cancer Portfolio With Forma Therapeutics Licensing PactAugust 2, 2022 | finance.yahoo.comRigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid LeukemiaJuly 29, 2022 | finance.yahoo.comForma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022July 12, 2022 | finance.yahoo.comForma Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)July 8, 2022 | finance.yahoo.comHow Much Upside is Left in Forma Therapeutics Holdings, Inc. (FMTX)? Wall Street Analysts Think 379%June 30, 2022 | finance.yahoo.comForma Therapeutics Announces Appointment of New Executive Team MembersJune 22, 2022 | finance.yahoo.comCan Forma Therapeutics Holdings, Inc. (FMTX) Climb 536% to Reach the Level Wall Street Analysts Expect?June 15, 2022 | finance.yahoo.comBears are Losing Control Over Forma Therapeutics Holdings, Inc. (FMTX), Here's Why It's a 'Buy' NowJune 13, 2022 | finance.yahoo.comRead Why Forma Therapeutics' Current Price Level Is 'Attractive Entry Point'June 3, 2022 | finance.yahoo.comForma Therapeutics to Present at the Jefferies Healthcare ConferenceMay 26, 2022 | finance.yahoo.comForma Therapeutics Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline at Inaugural Research and Development (R&D) DayMay 8, 2022 | finance.yahoo.comCompanies Like Forma Therapeutics Holdings (NASDAQ:FMTX) Are In A Position To Invest In GrowthSee More Headlines Receive FMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Forma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FMTX CUSIPN/A CIK1538927 Webwww.formatherapeutics.com Phone617-679-1970FaxN/AEmployees166Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-172,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.68% Return on Assets-35.33% Debt Debt-to-Equity RatioN/A Current Ratio12.74 Quick Ratio12.74 Sales & Book Value Annual Sales$100.56 million Price / Sales9.52 Cash FlowN/A Price / Cash FlowN/A Book Value$10.51 per share Price / Book1.90Miscellaneous Outstanding Shares47,853,000Free Float45,082,000Market Cap$957.54 million OptionableNot Optionable Beta-0.94 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Frank D. Lee (Age 54)Pres & CEO Comp: $963.2kMr. Todd E. Shegog (Age 56)Sr. VP & CFO Comp: $620.25kDr. John E. Bishop Ph.D. (Age 60)Sr. VP & Chief Technology Officer Dr. David N. Cook Ph.D. (Age 64)Sr. VP & Chief Scientific Officer Mr. Mario Vincent Corso C.F.A.Head of Investor RelationsDr. Jeannette Potts J.D. (Age 60)Ph.D., Sr. VP, Gen. Counsel & Corp. Sec. Ms. Xuandai Nguyen Ph.D.VP of Commercial Strategy & MarketingMs. Linea Aspesi (Age 52)Sr. VP & Chief HR Officer Mr. Brian Lesser (Age 47)Sr. VP of Commercial Dr. Ifeyinwa Osunkwo M.D.M.P.H., Sr. VP & Chief Patient OfficerMore ExecutivesKey CompetitorsBioCryst PharmaceuticalsNASDAQ:BCRXImmaticsNASDAQ:IMTXKyverna TherapeuticsNASDAQ:KYTXVir BiotechnologyNASDAQ:VIRAdaptimmune TherapeuticsNASDAQ:ADAPView All Competitors FMTX Stock Analysis - Frequently Asked Questions How were Forma Therapeutics' earnings last quarter? Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.05. During the same period last year, the firm posted ($0.67) earnings per share. What other stocks do shareholders of Forma Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Forma Therapeutics investors own include Boeing (BA), Marvell Technology (MRVL), Trade Desk (TTD), Abbott Laboratories (ABT), CVS Health (CVS), Walt Disney (DIS), DocuSign (DOCU), Gilead Sciences (GILD), Intuit (INTU) and Neurocrine Biosciences (NBIX). When did Forma Therapeutics IPO? Forma Therapeutics (FMTX) raised $201 million in an initial public offering (IPO) on Friday, June 19th 2020. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. Jefferies' SVB Leerink and Credit Suisse served as the underwriters for the IPO. This page (NASDAQ:FMTX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm PressTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forma Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
